viernes, 24 de mayo de 2019

More reads

The Readout
Damian Garde

More reads

  • NYSE cuts fees to court biotech listings away from Nasdaq. (Wall Street Journal)
  • Vertex and U.K. agency are still haggling over cystic fibrosis drugs. (STAT Plus)
  • Biotech tide may turn as large deals are shunned, Citi says. (Bloomberg)
  • Glaxo revamps sales rep compensation as part of an effort to compete in the cancer market. (STAT Plus)

No hay comentarios: